2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3525 Validation of RHL4S, a spatially resolved prognostic biomarker, in relapsed/refractory classic Hodgkin lymphoma

Yusuke Toda, MD, PhD, Chathuri Abeyakoon, MD2, Yifan Yin, PhD3, Aixiang Jiang, PhD4, Joseph Lownik, MD, PhD5, Katy Milne6, Natalie Taylor7, Kassandra Sewell8, Marinoni Massimiliano9, Inna Gong, MD, PhD10, Abi Vijenthira, MD, MS11, Michael Crump, MD12, Anca Prica13, Robert Kridel, MD14, John Kuruvilla, MD15, Brad H Nelson16, Christian Steidl, MD17, Akil Merchant I, MD18, Arjan Diepstra, MD, PhD19, Tomohiro Aoki, MD, PhD20
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 BC Cancer, Vancouver, British Columbia, Canada
4 BC Cancer, Vancouver, British Columbia, Canada
5 Cedars-Sinai Medical Center, West Hollywood, California, United States
6 BC Cancer, Victoria, British Columbia, Canada
7 BC Cancer, Victoria, British Columbia, Canada
8 BC Cancer, Victoria, British Columbia, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
15 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
16 BC Cancer, Victoria, British Columbia, Canada
17 BC Cancer, Vancouver, British Columbia, Canada
18 Cedars-Sinai Medical Center, West Hollywood, California, United States
19 University Medical Center Groningen, Groningen, Groningen, Netherlands
20 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada

Introduction: Classic Hodgkin lymphoma (cHL) is characterized by a unique tumor microenvironment (TME), in which malignant Hodgkin and Reed-Sternberg (HRS) cells comprise less than 1% of the total tumor cellularity and are surrounded by abundant reactive immune cells. Consequently, extensive efforts have focused on characterizing the TME to identify clinically relevant biomarkers in cHL. More recently, studies have demonstrated that, beyond the relative abundance of individual immune cell subsets, the spatial organization of the TME is a critical determinant of clinical outcome. Building on these findings, we previously developed RHL4S, a spatially resolved prognostic biomarker that integrates TME architecture to identify high-risk patients with relapsed/refractory (r/r) cHL undergoing high-dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT) (Aoki et al., J Clin Oncol. 2024). However, RHL4S has not yet been independently validated in an external cohort. Therefore, in the present study, we sought to independently validate the prognostic performance of RHL4S in an external patient cohort.

Methods: We performed a multi-color immunofluorescence (MC-IF) assay on formalin-fixed paraffin-embedded (FFPE) tissue specimens at relapse from 64 patients with r/r cHL treated at Princess Margaret Cancer Centre, the University Medical Center Groningen, and Cedars-Sinai Medical Center using a customized marker panel (CD30, CXCR5, CD4, PD-1, CD68, and CD20). All patients underwent HDC/ASCT between 1993 and 2024. Patients who received brentuximab vedotin and/or PD-1 blockade before HDC/ASCT and/or as a consolidative treatment were defined as the novel treatment group. Spatial scores were calculated based on the distances between HRS cells and their five nearest neighboring cells of each cell type, with distances capped at 50 µm. RHL4S was calculated using the spatial scores of four variables (CXCR5+ HRS, PD-1+ CD4+ T cells, CD68+ macrophages, and CXCR5+ B cells). Post-ASCT overall survival (OS) and post-ASCT progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Pairwise multivariable Cox proportional hazards models adjusting for previously reported clinical prognostic factors, including age at ASCT (≥45 vs <45 years), sex (male vs female), and early relapse (time from the end of treatment to first relapse <12 vs ≥12 months), were additionally performed to assess the independent prognostic value of RHL4S.

Results: The baseline characteristics at relapse of the 64 patients were as follows: the median age was 33 years (range, 18–63), and 59% of patients were male. Forty-six percent of patients relapsed within 12 months (early relapse). The MC-IF-based RHL4S assay classified 35 patients as low risk and 29 as high risk. After a median follow-up of 6.9 years following ASCT, patients in the RHL4S high-risk group had significantly inferior post-ASCT PFS compared with those in the low-risk group (5-year post-ASCT PFS, 32% vs. 64%; P = 0.029). Five-year post-ASCT OS was 73% versus 89%, respectively (P = 0.26). After adjustment for age ≥45 years at ASCT, sex (male), and early relapse in separate pairwise multivariable Cox models, RHL4S remained independently associated with post-ASCT PFS (HRs 2.31 [95% CI 1.06–4.54], 2.30 [1.10–4.78], and 1.72 [0.80–3.71]; P = 0.034, P = 0.026, and P = 0.168, respectively), with the last showing a trend.

Subgroup analyses of patients treated with novel treatment (28% of the cohort) did not demonstrate significant differences in either post-ASCT PFS or OS between the RHL4S high-risk and low-risk groups (5-year post-ASCT PFS, 63% vs. 57%; P = 0.36; 5-year post-ASCT OS, 100% vs. 86%; P = 0.90). Notably, the CXCR5+ HRS cell spatial score showed an opposite prognostic association in patients treated with novel therapies compared with those receiving conventional therapy, although this difference did not reach statistical significance.

Conclusion: RHL4S was successfully validated in an independent multicenter cohort of patients with r/r cHL who underwent HDC/ASCT. However, its prognostic performance might be attenuated in patients treated with novel therapies, although the sample size was limited in this subgroup. These findings suggest that further comprehensive characterization of the TME in larger cohorts of patients treated with novel therapies is warranted.

Yusuke Toda, MD, PhD: No relevant conflicts of interest to declare.